| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
See Remarks
1 company
Chapman Marcus is a See Remarks at Seres Therapeutics, Inc.. Recent SEC Form 4 filings include 0 buys and 1 sell.
Estimated insider holdings value: $57K based on current market prices.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Nov 22, 2019 | MCRB Seres Therapeutics, Inc. | See Remarks | Sale+OE | 3,400 | $3.91 | $13,296.72 | -28.3% |